Performing Effective Corrective and Preventative Action

Posted by Sunil Sadhwani on Aug 4, 2020 5:22:09 AM

Performing an ideal clinical study would result in zero non-compliances throughout its entire life cycle. What an achievement that would be! Perhaps this is a utopian/non-realizable outcome, but wouldn’t it be great to avoid non-compliance issues resurfacing in the same study or perhaps in a follow on study. How does one incorporate lessons learned or experience from compliance issues to prevent recurrence? One clear approach is to thoroughly understand what caused the non-compliance –to get to that ‘a-ha’ moment. What’s the documentation process for recording the non-compliance? Is there a repository of non-compliances that is maintained to log these findings? Are there owners or actionees for these non-compliances to investigate them and close them within a reasonable time frame? As these questions are identified, a convergence of thought hopefully is achieved. If discipline is practiced to capture the specific issue as it is surfaced, it will be easier to get to root cause. It is likely some non-compliances are simple human error for which an effective Corrective and Preventative Action (CAPA) could be additional training of a site or study team members. When a critical non-compliance occurs warranting a larger stakeholder participation as its impact could very well jeopardize the study, the discipline for finding root cause should not deviate. Effort to focus on root cause taking advantage of tools such as Fishbone Diagrams to thoroughly evaluate all candidate root causes should take precedence. Only after root cause is understood should careful consideration on all available corrective actions and/or preventative actions be evaluated. To assess which appropriate corrective action to use, a Trade Space Evaluation methodology, often used in other industries, can be utilized. With this approach corrective actions are compared against a set of common criteria using numerical scoring metrics or color-coding metrics (Red, Yellow, or Green) to narrow down the optimal CAPA. Future blogs will illustrate how this methodology can be effective in the down-selection of the optimal CAPA. The key is to not to dilute the root cause process.   Risk assessments performed at the start of a study are key to predicting issues and pre-plan their mitigation. Incorporating a technique like the Trade Space Methodology in the CAPA process at this initial assessment and sustaining it through the study by maintaining the risk log with this additional information can result in a comprehensive closed loop CAPA process. Holding periodic and regular meetings with investigators and other study team members where non-compliances are reviewed and reported on further ensures a robust process. Depending on the size of the organization, having an independent QA resource focused on the overall non-compliance process and retaining the knowledge base can be an effective discipline. The Return on Investment for this discipline and rigor should be a downward trend in the number of non-compliances experienced through subsequent studies to get to the highly desirable zero non-compliances’ Study!

Read More

Topics: Clinical Research, Biotech, Pharmaceuticals, capa, Quality Assurance

Learn More From Us

We’re committed to quality and committed to meeting or exceeding your expectations.

Established to be your integrated Quality Assurance and Regulatory Compliance partner, with a laser focus on facilitating your clinical trial execution. Developing and supporting your quality initiatives from Day 1, the Harbor team is committed to quality through each functional service we provide.

We provide a hybrid of services which ensure all aspects of clinical trials meet quality assurance and regulatory standards – from study documentation, vendor oversight, and flexible resourcing throughout operations.

Watch our blog for articles that help you get the most from your clinical trials.

Subscribe Here!

Recent Posts